secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001140361-24-041100
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports positive Phase 1 data for brenetafusp in ovarian cancer at ESMO 2024
--------------------------------------------------------------------------------

- Phase 1 monotherapy: 58% disease control, 6.5% RECIST response rate, median PFS 3.3 months in heavily pre-treated platinum-resistant ovarian cancer.
- Phase 1 combo with chemo: 23% RECIST response rate, 69% disease control, 82% ctDNA molecular response rate.
- T cell fitness signature associated with OS (28 vs 11 months) and PFS (5 vs 2 months) for KIMMTRAK in uveal melanoma, across ImmTAC platform.
- Brenetafusp well tolerated; no treatment-related discontinuations; cytokine release syndrome manageable (57% Grade 1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124041100/0001140361-24-041100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124041100/ef20035872_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-041100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer